Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
7 minutes ago, 4:00 AM PST Via GlobeNewswire CHRS Share - Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor -
- Proceeds to fund development of key combination programs with LOQTORZI, including casdozokitug, a first-in-class, clinical-stage interleukin-27 (IL-27) antagonist, and CHS-114, a highly selective chemokine receptor 8 (CCR8) antibody -
- Post-closing proceeds to repay the entirety of the company's $230 million convertible notes due April 2026 -
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.